Feedback PLC UK Medical Device Certification for Bleepa
29 Juni 2021 - 8:00AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
29 June 2021
Reach announcement
Feedback plc
Bleepa affixed with a UK Medical Device Certification (UKCA)
-- UKCA regulatory certification further validates Bleepa technology
London, 29 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the specialist medical imaging technology company,
today announces that a UKCA mark, the post-BREXIT UK regulatory
certification, has been affixed to Bleepa, Feedback's flagship
medical imaging communications platform, adding to its portfolio of
regulatory approvals for Bleepa.
Dr Tom Oakley, CEO of Feedback, commented:
"In addition to the CE mark affixed last year, Bleepa has now
enhanced its regulatory technical file to include the UK's medical
Device Manufacturing mark. The new UK product marking is used for
goods being placed on the market in Great Britain post-BREXIT and
further validates as well as provides confidence in the quality and
expertise of Bleepa's technology."
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Feedback media:
Nick Mayhew, Chief Marketing Lead +44 (0) 7736 065353
Allenby Capital Limited (Nominated
Adviser)
David Worlidge / Vivek Bhardwaj +44 (0)20 3328 5656
Peterhouse Capital Limited (Joint
Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited
(Joint Broker)
Patrick Claridge / John Howes +44 20 3815 8880
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas 07980 541 893 or 07748 325 236 or
Johnson 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a medical imaging technology
business. Its core product, Bleepa, is a revolutionary medical
imaging communications app, providing an easy-to-use, high quality
tool to enable remote and secure communications between front-line
clinicians and teams. Importantly, it is the only CE marked medical
imaging communications platform on the NHSx clinical communications
tools framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS")-based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care facilitators. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of diagnosis.
About Reach announcements
This is a Reach announcement. Reach is an investor communication
service aimed at assisting listed and unlisted (including AIM
quoted) companies to distribute non-regulatory news releases into
the public domain. Information required to be notified under the
AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFIDRSITFIL
(END) Dow Jones Newswires
June 29, 2021 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024